The expression profiles of CD4low(HLA-G+) T cells
Ontology highlight
ABSTRACT:
ORGANISM(S): Mus musculus Homo sapiens
PROVIDER: GSE109844 | GEO | 2018/11/14
REPOSITORIES: GEO
Similar Datasets
Project description:Transcriptional profiling of mouse Prostate cancer cells comparing Pbsn-Cre LSL-KrasG12D P53L/L cells with Pbsn-Cre LSL-BrafV600E P53L/L cells, and to determine the effects of Kras or Braf mutantion on murine PCa gene expression.
2017-07-17 | GSE100919 | GEO
Project description:The aim of this study was to analyze critically the potential usefulness of selected RNA biomarkers in supporting conventional histological diagnostic tests for PCa. The selection of potential biomarkers was conducted by microarray profiling of gene expression on prostate tissues extracted from the gland after total radical prostatectomy. Gene expression profiles of 16 prostate samples without carcinoma and 16 matched pairs of samples with and without cancer cells isolated from prostates containing prostate carcinoma
2014-07-01 | E-GEOD-55597 | biostudies-arrayexpress
Project description:The aim of this study was to analyze critically the potential usefulness of selected DNA methylation biomarkers in supporting conventional histological diagnostic tests for PCa. The selection of potential biomarkers was conducted by microarray profiling of DNA methylation on prostate tissues extracted from the gland after total radical prostatectomy. DNA methylation profiles of 16 prostate samples without carcinoma and 16 matched pairs of samples with and without cancer cells isolated from prostates containing prostate carcinoma
2014-07-01 | E-GEOD-55598 | biostudies-arrayexpress
Project description:The aim of this study was to analyze critically the potential usefulness of selected RNA biomarkers in supporting conventional histological diagnostic tests for PCa. The selection of potential biomarkers was conducted by microarray profiling of gene expression on prostate tissues extracted from the gland after total radical prostatectomy.
2014-07-01 | GSE55597 | GEO
Project description:The aim of this study was to analyze critically the potential usefulness of selected DNA methylation biomarkers in supporting conventional histological diagnostic tests for PCa. The selection of potential biomarkers was conducted by microarray profiling of DNA methylation on prostate tissues extracted from the gland after total radical prostatectomy.
2014-07-01 | GSE55598 | GEO
Project description:Prostate cancer (PCa) is a leading male malignancy worldwide, with metabolic reprogramming being a critical hallmark of its progression. Extracellular vesicles (EVs) derived from tissues directly reflect the tumor microenvironment, offering unique insights into cancer pathophysiology that are unattainable through cell line or biofluid-derived EVs. However, the functional roles of tissue-derived EVs in PCa metabolism remain poorly understood. Leveraging our expertise in murine PCa model establishment and EV isolation from prostate tissue, this study aimed to characterize functional differences between PCa and normal prostate tissue via proteomic analysis of tissue-derived small EVs (sEVs). We orthotopically implanted luciferase-labeled PCa cells into nude mice to establish an in situ PCa model, confirmed tumor formation via in vivo imaging, and harvested tissues after four weeks. sEVs were isolated using ultracentrifugation combined with an iodixanol density cushion and characterized by transmission electron microscopy, nanoparticle tracking analysis, and protein marker profiling. Proteomic analysis identified 28 upregulated and 24 downregulated proteins in PCa-derived sEVs compared to normal controls. Subcellular localization revealed enrichment in the cytoplasm, while pathway analysis highlighted significant involvement in metabolic processes, particularly glycolysis, amino acid biogenesis, carbon metabolism, and pyruvate metabolism. Our study establishes a robust method for isolating prostate tissue sEVs and provides the first evidence that PCa tissue-derived sEVs exhibit profound metabolic pathway alterations. These findings enhance our understanding of PCa progression mechanisms and may facilitate the development of novel diagnostic biomarkers and therapeutic strategies targeting metabolic dysregulation in PCa.
2026-03-16 | PXD070089 | Pride
Project description:Prostate cancer (PCa) is a major public health issue in industrialized countries, mainly because of patients’ relapse by castration-refractory disease after androgen ablation. PCa progresses through a series of clinical states characterized by the extent of the disease, the hormonal status (castration-sensitive or castration-resistant) and the presence or absence of metastases. Progression to castration-resistant prostate cancer (CRPCa) involves several mechanisms such as ligand-independent androgen receptor activation and adaptive up-regulation of anti-apoptotic genes. CRPCa is highly aggressive and incurable, jeopardizing the patient’s quality of life and lifespan. Identifying the molecular events responsible for the progression to CRPCa is essential to avoid its development and design specific therapies. Despite the existing treatment guidelines for PCa and novel clinical trials for CRPCa, major challenges still remain for identifying specific CRPCa biomarkers and therapeutic targets for effective tailored therapy design for these patients. In this context, molecular profiling of human PCa may importantly contribute to the identification of new disease-specific biomarkers in order to improve PCa early diagnosis, prognosis and disease course and to predict strategies that help develop novel therapies. System-wide approaches such as transcriptomics and proteomics are nowadays applied to monitor molecular variations at the cellular level. Proteomics approaches offer a great potential for the discovery of novel biomarkers and the identification of new therapeutic agents by accurate quantification of proteins. Several studies have been published in the past where different proteomics approaches were used to identify PCa proteome. In the present study we analyzed the PCa proteome from several PCa cell lines representing different hormonal status of the disease to identify potential biomarkers differentially expressed in CRPCa.
2020-01-14 | PXD004970 | Pride
Project description:Prostate cancer (PCa) is a major public health issue in industrialized countries, mainly because of patients’ relapse by castration-refractory disease after androgen ablation. PCa progresses through a series of clinical states characterized by the extent of the disease, the hormonal status (castration-sensitive or castration-resistant) and the presence or absence of metastases. Progression to castration-resistant prostate cancer (CRPCa) involves several mechanisms such as ligand-independent androgen receptor activation and adaptive up-regulation of anti-apoptotic genes. CRPCa is highly aggressive and incurable, jeopardizing the patient’s quality of life and lifespan. Identifying the molecular events responsible for the progression to CRPCa is essential to avoid its development and design specific therapies. Despite the existing treatment guidelines for PCa and novel clinical trials for CRPCa, major challenges still remain for identifying specific CRPCa biomarkers and therapeutic targets for effective tailored therapy design for these patients. In this context, molecular profiling of human PCa may importantly contribute to the identification of new disease-specific biomarkers in order to improve PCa early diagnosis, prognosis and disease course and to predict strategies that help develop novel therapies. System-wide approaches such as transcriptomics and proteomics are nowadays applied to monitor molecular variations at the cellular level. Proteomics approaches offer a great potential for the discovery of novel biomarkers and the identification of new therapeutic agents by accurate quantification of proteins. Several studies have been published in the past where different proteomics approaches were used to identify PCa proteome. In the present study we analyzed the PCa proteome from several PCa cell lines representing different hormonal status of the disease to identify potential biomarkers differentially expressed in CRPCa.
2020-01-14 | PXD004992 | Pride
Project description:Prostate cancer (PCa) disseminated tumor cells (DTC) in the bone marrow (BM) can remain dormant for prolonged periods before recurrence. Our aim was to characterize individual prostate DTC, analyze tumor cell heterogeneity, and identify markers of tumor dormancy.
2014-09-16 | GSE48995 | GEO
Project description:In this study, we created a method to isolate prostate tissue small EVs, based on our knowledge of the murine prostate cancer model building. Our data suggested that prostate tissue small EVs proteins significantly changed in many metabolism pathways, such as Glycolysis, Biogenesis of amino acids, Carbon metabolism and Pyruvate metabolism. In this study, we are the first to report prostate tissue derived EVs proteins enriched in alterations of cancer metabolism. These differential proteins in PCa tissue EVs reflect metabolic changes in PCa and may provide insights into the development of early diagnostic biomarkers or novel therapeutic strategies.
2025-10-30 | PXD070085 |